A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Oct 31, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a treatment involving a medication called eravacycline for patients with a type of pneumonia caused by a tough bacteria known as carbapenem-resistant Acinetobacter baumannii (CRAB). The goal of the study is to see how effective and safe this combination therapy is for patients in China who are dealing with this serious infection. The trial aims to gather important information that can help improve treatment options for this type of pneumonia in the future.

To be eligible for this study, participants need to be at least 18 years old and should have a diagnosis of bacterial pneumonia with evidence of the CRAB infection. They must also be willing to participate by signing a consent form, which can be done by a legal guardian if the patient is unable to do so themselves. Participants will receive eravacycline treatment for at least three days. It’s important to note that individuals with certain medical histories or conditions, such as severe allergies to similar medications or life-threatening diseases, may not be able to join the trial. As of now, the study is not yet recruiting participants, but it will provide a valuable opportunity for those who qualify to potentially benefit from this new treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged 18 years or older.
• • 2. Voluntarily participating in this study and signing an informed consent form. If the subject is unable to read and/or sign the informed consent form due to lack of capacity or other reasons, the informed process and the informed consent form must be signed by their legal guardian.
• • 3. Patients with clinical manifestations and imaging results consistent with bacterial pneumonia, and who are expected to benefit from antimicrobial treatment. Suspected carbapenem-resistant Acinetobacter baumannii infection or Acinetobacter baumannii detected in two consecutive sputum cultures (at least one of which must be from bronchoalveolar lavage or endotracheal aspirate), with resistance to carbapenems.
• • 4. Patients who have been treated with eravacycline for at least 3 days.
• Exclusion Criteria:
• • 1. The investigator believes that there are any medical history, current condition, treatment, abnormal laboratory test results, or other situations that may affect the trial results, interrupt the trial process (or the subject cannot complete all trial requirements, operations, and visits), or increase the risk to the subject from receiving the trial medication, including patients with terminal illness, or evidence of an immediately life-threatening disease.
• • 2. Patients with a history of allergic reactions to tetracyclines or any excipients contained in the formulation of the study medication.